Skip to main content
Article
Translational Radiomics: Defining the Strategy Pipeline and Considerations for Application-Part 1: From Methodology to Clinical Implementation.
J Am Coll Radiol
  • Faiq A Shaikh, MD
  • Benjamin Franc, MD, MS, MBA
  • Erastus Allen, MBA
  • Evis Sala, MD, PhD
  • Omer Awan, MD, MPH
  • Kenneth Hendrata, MBA
  • Safwan Halabi, MD
  • Sohaib A Mohiuddin, MD, Lehigh Valley Health Network
  • Sana Malik, DrPH
  • Dexter Hadley, MD, PhD
  • Rasu Shrestha, MD, MBA
Publication/Presentation Date
3-1-2018
Abstract

Enterprise imaging has channeled various technological innovations to the field of clinical radiology, ranging from advanced imaging equipment and postacquisition iterative reconstruction tools to image analysis and computer-aided detection tools. More recently, the advancements in the field of quantitative image analysis coupled with machine learning-based data analytics, classification, and integration have ushered us into the era of radiomics, which has tremendous potential in clinical decision support as well as drug discovery. There are important issues to consider to incorporate radiomics as a clinically applicable system and a commercially viable solution. In this two-part series, we offer insights into the development of the translational pipeline for radiomics from methodology to clinical implementation (Part 1) and from that to enterprise development (Part 2).

PubMedID
29366600
Document Type
Article
Citation Information

Shaikh, F., Franc, B., Allen, E., Sala, E., Awan, O., Hendrata, K., … Shrestha, R. (2018). Translational Radiomics: Defining the Strategy Pipeline and Considerations for Application-Part 1: From Methodology to Clinical Implementation. Journal Of The American College Of Radiology: JACR, 15(3 Pt B), 538–542. https://doi.org/10.1016/j.jacr.2017.12.008